ConSynance Joins the Prader-Willi Syndrome Clinical Trial Consortium
March 11, 2019 09:00 ET
|
ConSynance Therapeutics, Inc.
Rensselaer, New York., March 11, 2019 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biotechnology company developing two innovative treatments for Prader-Willi Syndrome (PWS),...